Skip to main content

Alector FTD

All trials

Alzheimer

Alector FTD

Leeftijd icoon
18 - 85 years (M / F)
Diagnose icoon
Genetically confirmed C9orf72 mutation
Duratie onderzoek
112 weeks
Locatie icoon
Amsterdam

About this research

In order to participate in this study, you must be able to speak and read Dutch fluently.

A multicenter, open-label phase II study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of AL001 in heterozygous carriers of C9orf72 mutations leading to frontotemporal dementia.

The aim of this study is to find out how safe the new substance AL001 is and how well the substance is tolerated (i.e. looking for possible side effects) when given to subjects who have the genetically confirmed mutation in the granulin or C9orf72. gene. The study drug is administered by IV.

The research is carried out in the Brain Research Center Amsterdam.

This research is commissioned by Alector.

This text has been directly translated from the Dutch trial description as approved by the Ethical Committee.

Screening - Selection

During a maximum period of six weeks, it will be determined whether you meet the study criteria and whether your general health allows participation in the study. If so, you can participate. These examinations take place in Amsterdam and include blood tests, physical examinations, memory tests, ECG questionnaires, MRI, and a spinal tap.

Treatment

Each participant will receive AL001 (not a placebo/fake drug in this study). An IV treatment takes place every 4 weeks. In addition, appointments will be made with you when you should come to our center for check-ups (inquiries about side effects and medication use) and there will be physical and neurological examinations and neuropsychological examinations, blood tests, and ECGs and MRI scans will be made. The duration of treatment is 96 weeks.

Follow-up

After completion of the treatment phase, another visit is scheduled. During these visits, questionnaires and tests are taken for your memory, among other things. Furthermore, blood tests, physical examinations, an MRI scan, and/or a spinal tap will be performed.

Who can participate?

  • You have a genetically confirmed C9orf72 mutation
  • You are between 18 and 85 years old.
  • You have someone close to you who can accompany you during the visits to the research center and answer questions about your health and functioning, among other things.

Take action against Alzheimer’s. Sign up to participate.

Latest Dementia trials

Filter

All trialsAlzheimer

REMAD 02

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug REM0046127 is for the treatment of participants with mild to moderate Alzheimer’s disease. The study compares the effect of the new drug REM0046127 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50 - 85 years

levelMild to moderate Alzheimer's disease

duration9 weeks

locationAmsterdam

All trialsAlzheimer

APOLLOE4

The goal of this study is to evaluate how safe and effective the new drug…

The goal of this study is to evaluate how safe and effective the new drug ALZ-801 is for the treatment of participants with early-stage Alzheimer’s disease and ApoE4/4 genotype. The study compares the effect of the new drug ALZ-801 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is taken in the form of a tablet.

audience50 - 80 years

level Early-stage Alzheimer’s disease and ApoE4/4 genotype

duration93 weeks

locationAmsterdam, Den Bosch, and Zwolle

All trialsAlzheimer

Together

The goal of this study is to evaluate the safety and potential effectiveness of the…

The goal of this study is to evaluate the safety and potential effectiveness of the investigational drug (bepranemab) for participants with MCI or mild Alzheimer’s Disease. The study compares the effect of the active study drug bepranemab with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). Using a placebo will help us identify improvements or side effects which are caused by the active study medication. The study drug is administered through an intravenous (IV) injection.

audience50 - 80 years

levelMild cognitive impairment (MCI) or mild Alzheimer’s disease

duration152 weeks

locationAmsterdam, Den Bosch, and Zwolle